Support Alert

Class 4 Medicines Defect Information: Rifadin (rifampicin) 150mg Capsules (MDR 127-09/19)

Aventis Pharma Limited t/a Sanofi has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that a change to the Patient Information Leaflet, concerning possible side effects for Rifadin (rifampicin) 150mg Capsules, has not been implemented by the required timeline.

Loading...

Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.

RENEW YOUR MEMBERSHIP TODAY